Travaux scientifiques

Prof. Dr. İrfan Çiçin

345 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Economic burden of lung cancer in Turkey: a cost of illness study from payer 4 perspective, Irfan Cicin1, Ergun Oksuz2*, Nuri Karadurmus3, Simten Malhan4, , Mahmut Gumus5, , Ulku Yilmaz6, , Levent Cansever7, 6 Halit Cinarka7, , Erdogan Cetinkaya7, Murat Kiyik7, , Ahmet Ozet8, Health Econ Rev . 2021 Jun 26;11(1):22. doi: 10.1186/s13561-021-00322-2. (June 2021)

    Source : page de profil sur livhospital.com

  2. Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey. Özdemir K, Gürkan H, Demir S, Atli E, Özen Y, Sezer A, Tunçbilek N, Çicin I. Balkan J Med Genet. 2021 Mar 23;23(2):49-58. doi: 10.2478/bjmg-2020-0016. eCollection 2020 Nov. (April 2021)

    Source : page de profil sur livhospital.com

  3. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomized, controlled trial. Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, Igor Bondarenko, MustafaÖzgüroğlu, Miranda Gogishvili, Haci M Turk, Irfan Cicin, Dmitry Bentsion, Oleg Gladkov, Philip Clingan, Virote Sriuranpong, Naiyer Rizvi, Bo Gao, Siyu Li, Sue LeeKristina McGuire, Chieh-I Chen, Tamta Makharadze, Semra Paydas, Marina Nechaeva, Frank Seebach, David M Weinreich, George D Yancopoulos, Giuseppe Gullo, Israel Lowy, Petra Rietschel. Lancet 2021; 397: 592–604 (February 2021)

    Source : page de profil sur livhospital.com

  4. Merkel cell carcinoma in Turkey: A multicentric study Fatih Yildiz1, Umut Demirci1, Ahmet Küçükarda2, Mahmut Büyüksimsek3, Teoman Sakalar4, Turkan Ozturk Topcu5, Ferit Aslan1, Gulnihal Tufan1, Ovgu Aydin6, Hande Turna7, Nalan Akgul Babacan8, Tugba Basoglu8, Bediz Kurt9, Birol Yildiz10, Tülay Eren11, Atike Gokcen Demiray12, Ozge Gumusay13, Cagatay Arslan14, Nuriye Özdemir15, Yuksel Urun16, Meltem Baykara17, Nedim Turan18, Mukremin Uysal19, Ahmet Bilici20, Halil Kavgaci5, İrfan Çiçin2, Saadettin Kilickap21, Semra Paydas3, DOI: 10.4103/jcrt.JCRT_950_19.JCRT,Dec2020 (December 2020)

    Source : page de profil sur livhospital.com

  5. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR1, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Stephen R. D. Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martin, Zhi Min Shao, Qing Yuan Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton, Joohyuk Sohn, Valentina Guarneri, Morihito Okada, Frances Boyle, Patrick Neven, Javier Cortes, Jens Huober, Andrew Wardley, Sara M. Tolaney, Irfan Cicin, Ian C. Smith, Martin Frenzel, Desiree Headley, Ran Wei, Belen San Antonio, Maarten Hulstijn, Joanne Cox, Joyce O’Shaughnessy, and Priya Rastogi, on behalf of the monarchE Committee Members and InvestigatorsDOI: 10.1200/JCO.20.02514 Journal of Clinical Oncology (September 2020)

    Source : page de profil sur livhospital.com

  6. Evaluating sun protection behaviors and skin self-examination practices among the family members of melanoma patients in Turkey: A cross-sectional survey study. Sarikaya Solak S, Yondem H, Cicin I. Dermatol Ther. 2020 Sep 3:e14268. doi: 10.1111/dth.14268. (September 2020)

    Source : page de profil sur livhospital.com

  7. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407. Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Parra HS, Mazières J, Hermes B, Cicin I, Medgyasszay B, Cid JR, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B. J Thorac Oncol. 2020 Jun 26:S1556-0864(20)30500-1. doi: 10.1016/j.jtho.2020.06.015 (June 2020)

    Source : page de profil sur livhospital.com

  8. Targeted next-generation sequencing as a diagnostic tool in gastrointestinal system cancer/polyposis. Yalcintepe S, Gurkan H, Demir S, Tozkir H, Tezel HA, Atli EI, Atli E, Eker D, Cicin I.Tumori. 2020 May 11:300891620919171. doi: 10.1177/0300891620919171. (May 2020)

    Source : page de profil sur livhospital.com

  9. Rachel Riechelmann, Vichien Srimuninnimit, Roberto Bordonaro, Petr Kavan, Maria Di bartolomeo, evaristo maiello, irfan cicin, Pilar García Alfonso, Ian Chau, Mikhail Fedyanin, Carlos Fernández-Martos, Mikhail Ter-Ovanesov, Marc Peeters, Yoo-Joung Ko, suayib yalcin, Meinolf Karthaus, Jorge Aparicio, Volker Heinemann, Pascaline Picard, Denise Bury, Edward Drea, Alberto SobreroAflibercept plus FOLFIRI for Second-Line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP) , Clinical Colorectal Cancer May 2019DOI: https://doi.org/10.1016/j.clcc.2019.05.003 (May 2019)

    Source : page de profil sur livhospital.com

  10. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer. Köstek O, Demircan NC, Gökyer A, Küçükarda A, Sunal BS, Hacıoğlu MB, Eslame H, Solak S, Yılmaz E, Uzunoğlu S, Tunçbilek N, Çiçin I, Erdoğan B.Clin Transl Oncol. 2019 Mar 28. doi: 10.1007/s12094-019-02079-x (March 2019)

    Source : page de profil sur livhospital.com

  11. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenibGökyer A, Küçükarda A, Köstek O, Hacıoğlu MB, Sunal BS, Demircan NC, Uzunoğlu S, Solak S, İşsever K, Çiçin I, Erdoğan B. . Clin Transl Oncol. 2019 Mar 13. doi: 10.1007/s12094-019-02080-4. (March 2019)

    Source : page de profil sur livhospital.com

  12. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Cancer Chemother Pharmacol. 2018 Oct 30. doi: 10.1007/s00280-018-3712-7. (November 2018)

    Source : page de profil sur livhospital.com

  13. 6MO - Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC With PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up. D. Rodriguez Abreu1, M. Reck2, M.A..N. Sendur3, K. Park4, D.H. Lee5, I. Cicin6, P.F. Yumuk7, F.J. Orlandi8, T.A. Leal9, N. Soparattanapaisarn10, A. Langleben11, R. Califano12, B. Medgyasszay13, T. Hsia14, G.A. Otterson15, T. Woods16, E. Jensen16, A. Samkari16, M. Boyer17, Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856. ESMO2022 (September 2022)

    Source : page de profil sur livhospital.com

  14. Three-Year Survival Outcome and Continued Cemiplimab Beyond Progression with the Addition of Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with PD-L1 ≥50%: The EMPOWER-Lung 1 Trial Mustafa Özgüroğlu,1 Saadettin Kilickap,2 Ahmet Sezer,3 Mahmut Gumus,4 , Igor Bondarenko,5 Miranda Gogishvili,6 Marina Nechaeva,7 Michael Schenker,8, Irfan Cicin,9 Ho Gwo Fuang,10 Yaroslav Kulyaba,11 Mikhail Dvorkin,12 Kasimova, Zyuhal,13 Roxana-Ioana Scheusan,14 Manika Kaul,15 Emmanuel Okoye,15 Yuntong Li,15 Xuanyao He,15 Siyu Li,15 Jean-Francois Pouliot,15 Frank Seebach,15, Israel Lowy,15 Giuseppe Gullo,15 Petra Rietschel15 ESMO 2022 (September 2022)

    Source : page de profil sur livhospital.com

  15. 63P. Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- high-risk early breast cancer .Shani Paluch-Shimon1 , Patrick Neven2 , Jens Huober3 , Irfan Cicin4 , Matthew P. Goetz 5 , Chikako Shimizu6 , Chiun-Sheng Huang7 , Ran Wei 8 , Sarah C. Nabinger , Tammy Forrester 8 , Nadia Harbeck 9 ESMO Breast 2022 (May 2022)

    Source : page de profil sur livhospital.com

  16. D. Ross Camidge, Fedor Moiseenko, Irfan Cicin, Hidehito Horinouchi, Elena Filippova, Jair Bar, Shun Lu, Pascale Tomasini, Christopher Ocampo, Danielle Sullivan, David Maag, Jonathan W. Goldman. Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT179. (July 2021)

    Source : page de profil sur livhospital.com

  17. Quality of life and subgroup analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3. Authors: G. Selvaggi1 , Y.-L. Wu 2 Z. Wang3, G. Wu4, E. Poddubskaya5, M. Reck6, T. Mok7, A. Chiappori8, D.H. Lee9 , V.Breder10, S. Orlov11, I. Cicin12, Y. Cheng13, Y. Liu14, Y. Fan15, J. Zhou1 , C. Liang16 , L. Mao1 , L. Horn17 , H.A. Wakelee18 ; 1 WCLC, January 28 - 31, 2021 (January 2021)

    Source : page de profil sur livhospital.com

  18. EMPOWER-Lung 1: Clinical benefits of first-line (1L) cemiplimab monotherapy by PD-L1 expression levels in patients with advanced NSCLC

    Source : page de profil sur livhospital.com

  19. Saadettin Kilickap,1 Ahmet Sezer,2 Mahmut Gümüş,3 Igor Bondarenko,4 Mustafa Özgüroğlu,5 Miranda Gogishvili,6 Haci M Turk,7 Irfan Cicin,8 Dmitry Bentsion,9 Oleg Gladkov,10 Philip Clingan,11 Virote Sriuranpong,12 Naiyer Rizvi,13 Siyu Li,14 Sue Lee,14 Tamta Makharadze,15 Semra Paydas,16 Marina Nechaeva,17 Frank Seebach,18 David M Weinreich,18 George D Yancopoulos,18

    Source : page de profil sur livhospital.com

  20. Giuseppe Gullo,18 Israel Lowy,18 Petra Rietschel18 January 28 - 31, 2021, WCLC (January 2021)

    Source : page de profil sur livhospital.com

  21. Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3 G Selvaggi, HA Wakelee, T Mok, YL Wu, M Reck, A Chiappori, I Cicin, ... Journal of Thoracic Oncology 15 (10), e41-e42 (October 2020)

    Source : page de profil sur livhospital.com

  22. EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. A. Sezer1, S. Kilickap2, M. Gümüş3, I. Bondarenko4, M. Özgüroğlu5, M. Gogishvili6, H.M. Turk7, İ. Çiçin8, D. Bentsion9, O. Gladkov10, P. Clingan11, V. Sriuranpong12, N. Rizvi13, S. Li14, S. Lee14, G. Gullo15, I. Lowy15, P. Rietschel15. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. ESMO2020 (September 2020)

    Source : page de profil sur livhospital.com

  23. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access Gul Basaran, Umut Demirci, Fatih Yildiz, Irfan Cicin, Burak Yasin Aktas, Banu Ozturk, Sema Sezgin Goksu, Hasan Senol Coskun, Basak Oyan, Ozlem Sonmez, Yesim Eralp, Erhan Gokmen, Seyda Gunduz, Taner Korkmaz, Mehmet Ali Nahit Sendur, Serkan Keskin, ASCO-2020 Journal of Clinical Oncology 38 (15_suppl), e13055-e13055 (May 2020)

    Source : page de profil sur livhospital.com

  24. P-209 Multicenter real life experience of biological agents in patients with metastatic colorectal cancerU Demirci, I Ertürk, Ç Arslan, A Bilici, D Çevik, I Cicin, F Dane, B Dölek, M Kaplan, N Karadurmuş, F Kose, M Şendur, Y Ürün, S Kılıçkap Annals of Oncology 31, S158 ESMO GI-2020 (May 2020)

    Source : page de profil sur livhospital.com

  25. Kilickap, S., et al. "Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?." ANNALS OF ONCOLOGY. Vol. 30. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS, 2019. (November 2019)

    Source : page de profil sur livhospital.com

  26. Real-world assessment of clinical effectiveness and safety of pazopanib in patients with advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: A prospective, observational study (PARACHUTE) R Kanesvaran, B Biswas, P Danchaivijitr, C S Lim, B Karabulut, Y F Wong, H S Coskun, C-H Chang, I Cicin, S Ingles, K Slimane, M Erman Annals of Oncology, Volume 30, Issue Supplement_9, November 2019, mdz446.008, https://doi.org/10.1093/annonc/mdz446.008 (November 2019)

    Source : page de profil sur livhospital.com

  27. Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 L. Paz-Ares1, , D. Vicente2, , A. Tafreshi3 ,, A. Robinson4, H. Soto Parra5, J. Mazie`res6 ,B. Hermes7, I. Cicin8 , B. Medgyasszay9 , B. Beatrix10, J. Rodrıguez Cid11, I. Okamoto12, S. Lee13, R. Ram, ESM0 2019, Barcelona (October 2019)

    Source : page de profil sur livhospital.com

  28. S.L. Chan1, R. Miksad2, I. Cicin3, Y. Chen4, H.J. Klumpen5, S. Kim6, Z.Z. Lin7, J. Youkstetter8, S. Sen8, A. Cheng9, A.B. El-Khoueiry10, T. Meyer11, R.K. Kelley12, G.K. Abou-Alfa1Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC) Annals of Oncology (2019) 30 (suppl_9): ix42-ix67. 10.1093/annonc/mdz422 (June 2019)

    Source : page de profil sur livhospital.com

  29. 1401P The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey. S Kilickap, Ö F Ölmez, I Cicin, U Demirci, O Alan, D Cabuk, T Şakalar, AM Tatlı, F Başol Buğdaycı, Y Eralp, M Uysal, A Demirkazık, B Bilgin, B Yıldız, M Karaağaç, K Okutur, A Sakin. Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018, mdy292.023, (October 2018)

    Source : page de profil sur livhospital.com

  30. Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC. Balazs Halmos,1 Alexander Luft,2 Margarita Majem,3 Rina Hui,4 Romain Corre,5 Mahmut Gümüş,6 Konstantin Laktionov,7 Barbara Hermes,8 Irfan Cicin,9 Andrew G. Robinson,10 Terufumi Kato,11 Ying Cheng,12 Dariusz Kowalski,13 Xiaodong Li,14 Gregory M. Lubiniecki,14 Bilal Piperdi,14 Luis Paz-Ares15, Toronto (September 2018)

    Source : page de profil sur livhospital.com

  31. R. Riechelmann1, V. Srimuninnimit2, P. Kavan3, M. Di Bartolomeo4, E. Maiello5, I. Cicin6, H. Kröning7, P. Garcia-Alfonso8, I. Chau9, C. Fernández-Martos10, M. Ter-Ovanesov11, M. Peeters12, P. Picard13, R. Bordonaro14Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP) ESMO2016 (October 2016)

    Source : page de profil sur livhospital.com

  32. Low molecular weight heparin (LMWH) treatment in cancer patients with low risk venous thromboembolism - results of Turkish Observational Study (TREBECA) By: Ozkan, M.; Cicin, I.; Ozaslan, E.; et al. Conference: European Cancer Congress Location: Vienna, AUSTRIA Date: 2015 EUROPEAN JOURNAL OF CANCER Volume: 51 Supplement: 3 Pages: S245-S245 Meeting Abstract: 1619 Published: SEP 2015

    Source : page de profil sur livhospital.com

  33. Uygun, K., I. Cicin, H. Kargol, S. Uzunoglu, Z. Kocak, M. Caloglu ve P. Saip, “The treatment results of patients with extra-pulmoner and pulmoner small cell Cancer,” 31st The European Society for Medical Oncology Congress, Istanbul, Vol. 17, suppl 9, 240, Poster sunu 816, Annals of Oncology, 2006.

    Source : page de profil sur livhospital.com

  34. Uygun, K., I. Cicin, H. Karagol, P. Saip ve S. Uzunoglu, “Second line chemotherapy non small cell lung carcinoma: A single-institution experience” 31st The European Society for Medical Oncology Congress, Istanbul, Vol. 17, suppl 9, 239, Poster sunu 812, Annals of Oncology, 2006.

    Source : page de profil sur livhospital.com

  35. Uygun, K., H. Karagol, M. Caloglu, I. Cicin, VY. Caloglu, S. Uzunoglu ve P. Saip, “The Comparison of weekly And 3-weekly cisplatin chemotherapy concurrent with radiotherapy in patient with previously untreated inoperable non-metastatic SCCHN,” 31st The European Society for Medical Oncology Congress, Istanbul, Vol. 17, suppl 9, 182, Poster sunu 585, Annals of Oncology, 2006.

    Source : page de profil sur livhospital.com

  36. Uygun K., H. Karagöl, İ Çiçin, F Tokatlı, Z Koçak, “Adjuvant chemotherapy in the treatment of curatively resected gastric cancer: as single oncology center experience”, American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, San Francisco, USA, Poster sunu 76, 2006.

    Source : page de profil sur livhospital.com

  37. Cicin I., M. Demir, O.Vural, B. Turgut ve M. Vurkun, “Distribution of haptoglobin subtypes in a Turkish Population from Edirne (East Trakya)-Turkey,” 7th Meeting of the European Hematology Association, Abstract Book, 65, Poster sunu 184, , Florence (2002)

    Source : page de profil sur livhospital.com

  38. Clinical Research at MENA, Ed: Ozdener.Role of Investigator, İrfan Çiçin, Ali Gökyer, p:41-70 Peter, Lang, Wien, 2021 F. ISBN 978-3-631-81113-9 (Print) E-ISBN 978-3-631-86385-5 (E-PDF), E-ISBN 978-3-631-86386-2 (EPUB) (November 2021)

    Source : page de profil sur livhospital.com

  39. Clinical features of the patient with multiple primary tumors: Single center experience (May 2017)

    Source : page de profil sur livhospital.com

  40. How Many Lines of Chemotherapy Should Be Applied in Metastatic Non-Small Cell Lung Cancer? Sernaz UZUNOĞLU, İrfan ÇİÇİN. Turkiye Klinikleri J Med Oncol-Special Topics 2016;9(4):56-64 (December 2016)

    Source : page de profil sur livhospital.com

  41. Systemic Chemotherapy in Ovarian Germ Cell and Stromal Cancers, Sernaz UZUNOĞLU, İrfan ÇİÇİN, Turkiye Klinikleri J Med Oncol-Special Topics 2016;9(1):41-51 (April 2016)

    Source : page de profil sur livhospital.com

  42. A case of Guillain-Barre syndrome in a patient with small cell lung cancer treated with chemotherapy Esma TÜRKMEN1, Bülent ERDOĞAN1, İlhan HACIBEKİROĞLU1 Hilmi KODAZ1, Sernaz Uzunoğlu1, Yahya ÇELİK2, İrfan ÇİÇİN1Türk Onkoloji Dergisi 2014;29(3):104-107 (September 2014)

    Source : page de profil sur livhospital.com

  43. Chemotherapy and Targeted Therapy in Castration Resistant Prostate Cancer Sernaz UZUNOĞLUa, İrfan ÇİÇİN Turkiye Klinikleri J Urology-Special Topics 2014;7(4):108-17

    Source : page de profil sur livhospital.com

  44. Hypothermia in Hodgkin’s disease: unexpected state; case report and rewiew of the literature Türk Onkoloji Dergisi 2013;28(1):41-43

    Source : page de profil sur livhospital.com

  45. Treatment of Primary Tumors Relapsed or Refractory Glial and Targeted Therapies S UZUNOĞLU, İ ÇİÇİN Turkiye Klinikleri J Med Oncol-Special Topics 2013;6(1):43-9

    Source : page de profil sur livhospital.com